Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CASP3 | P42574 | 2/20 | 0.54 |
| ▸ | TLR2 | O60603 | 2/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31276348 | 1.00 | MDM4 (0.59) | MDM4TP53KMT2ACASP3TLR2 | |
| SCHEMBL29455664 | 1.00 | MDM4 (0.59) | MDM4TP53KMT2ACASP3TLR2 | |
| SCHEMBL119637 | 1.00 | MDM4 (0.59) | MDM4TP53KMT2ACASP3TLR2 | |
| SCHEMBL5967446 | 1.00 | MDM4 (0.59) | MDM4TP53KMT2ACASP3TLR2 | |
| SCHEMBL29528770 | 1.00 | MDM4 (0.59) | MDM4TP53KMT2ACASP3TLR2 | |
| SCHEMBL15806918 | 0.94 | MDM4 (0.56) | MDM4TP53KMT2ACASP3TLR2 | |
| SCHEMBL25168212 | 0.93 | MDM4 (0.53) | MDM4TP53KMT2ACASP3TLR2 | |
| SCHEMBL6290889 | 0.93 | MDM4 (0.53) | MDM4TP53KMT2ACASP3TLR2 | |
| SCHEMBL22552830 | 0.93 | MDM4 (0.53) | MDM4TP53KMT2ACASP3TLR2 | |
| SCHEMBL31220290 | 0.93 | MDM4 (0.53) | MDM4TP53KMT2ACASP3TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220288213-A1 | INSULIN ANALOGUES WITH GLUCOSE REGULATED CONFORMATIONAL SWITCH | THERMALIN INC (US) | 2022-09-15 | — | — | US | disclosed |
| US-20220184184-A1 | GLUCOSE SENSITIVE INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2022-06-16 | — | — | US | disclosed |
| EP-4003426-A1 | INSULIN ANALOGUES WITH GLUCOSE REGULATED CONFORMATIONAL SWITCH | Thermalin Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-3946363-A2 | GLUCOSE SENSITIVE INSULIN DERIVATIVES | Novo Nordisk A/S (DK) | 2022-02-09 | — | — | EP | disclosed |
| WO-2021022116-A1 | INSULIN ANALOGUES WITH GLUCOSE REGULATED CONFORMATIONAL SWITCH | THERMALIN INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| WO-2020201041-A2 | GLUCOSE SENSITIVE INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2020-10-08 | — | — | WO | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220184184-A1 | GLUCOSE SENSITIVE INSULIN DERIVATIVES | IAPP, IRS1, GPR119 | MDM4 2541/4885TP53 1570/4885KMT2A 4867/4885 |
| US-20220288213-A1 | INSULIN ANALOGUES WITH GLUCOSE REGULATED CONFORMATIONAL SWITCH | IAPP, GPR119, INSR | MDM4 3630/4885TP53 3210/4885KMT2A 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.